The emerging role of tranexamic acid and its principal target, plasminogen, in skeletal health

Weixin Xie; Antonia Donat; Shan Jiang; Anke Baranowsky; Johannes Keller

doi:10.1016/j.apsb.2024.03.033

The emerging role of tranexamic acid and its principal target, plasminogen, in skeletal health

Standard

The emerging role of tranexamic acid and its principal target, plasminogen, in skeletal health. / Xie, Weixin; Donat, Antonia; Jiang, Shan; Baranowsky, Anke; Keller, Johannes.

In: ACTA PHARM SIN B, Vol. 14, No. 7, 07.2024, p. 2869-2884.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Xie, W, Donat, A, Jiang, S, Baranowsky, A & Keller, J 2024, 'The emerging role of tranexamic acid and its principal target, plasminogen, in skeletal health', ACTA PHARM SIN B, vol. 14, no. 7, pp. 2869-2884. https://doi.org/10.1016/j.apsb.2024.03.033

APA

Xie, W., Donat, A., Jiang, S., Baranowsky, A., & Keller, J. (2024). The emerging role of tranexamic acid and its principal target, plasminogen, in skeletal health. ACTA PHARM SIN B, 14(7), 2869-2884. https://doi.org/10.1016/j.apsb.2024.03.033

Vancouver

Xie W, Donat A, Jiang S, Baranowsky A, Keller J. The emerging role of tranexamic acid and its principal target, plasminogen, in skeletal health. ACTA PHARM SIN B. 2024 Jul;14(7):2869-2884. https://doi.org/10.1016/j.apsb.2024.03.033

Bibtex

@article{24bce7d8aeda4660b7ae6886a8dbf2ba,

title = "The emerging role of tranexamic acid and its principal target, plasminogen, in skeletal health",

abstract = "The worldwide burden of skeletal diseases such as osteoporosis, degenerative joint disease and impaired fracture healing is steadily increasing. Tranexamic acid (TXA), a plasminogen inhibitor and anti-fibrinolytic agent, is used to reduce bleeding with high effectiveness and safety in major surgical procedures. With its widespread clinical application, the effects of TXA beyond anti-fibrinolysis have been noticed and prompted renewed interest in its use. Some clinical trials have characterized the effects of TXA on reducing postoperative infection rates and regulating immune responses in patients undergoing surgery. Also, several animal studies suggest potential therapeutic effects of TXA on skeletal diseases such as osteoporosis and fracture healing. Although a direct effect of TXA on the differentiation and function of bone cells in vitro was shown, few mechanisms of action have been reported. Here, we summarize recent findings of the effects of TXA on skeletal diseases and discuss the underlying plasminogen-dependent and -independent mechanisms related to bone metabolism and the immune response. We furthermore discuss potential novel indications for TXA application as a treatment strategy for skeletal diseases.",

author = "Weixin Xie and Antonia Donat and Shan Jiang and Anke Baranowsky and Johannes Keller",

note = "{\textcopyright} 2024 The Authors.",

year = "2024",

month = jul,

doi = "10.1016/j.apsb.2024.03.033",

language = "English",

volume = "14",

pages = "2869--2884",

journal = "ACTA PHARM SIN B",

issn = "2211-3835",

publisher = "Chinese Academy of Medical Sciences",

number = "7",

}

RIS

TY - JOUR

T1 - The emerging role of tranexamic acid and its principal target, plasminogen, in skeletal health

AU - Xie, Weixin

AU - Donat, Antonia

AU - Jiang, Shan

AU - Baranowsky, Anke

AU - Keller, Johannes

PY - 2024/7

Y1 - 2024/7

N2 - The worldwide burden of skeletal diseases such as osteoporosis, degenerative joint disease and impaired fracture healing is steadily increasing. Tranexamic acid (TXA), a plasminogen inhibitor and anti-fibrinolytic agent, is used to reduce bleeding with high effectiveness and safety in major surgical procedures. With its widespread clinical application, the effects of TXA beyond anti-fibrinolysis have been noticed and prompted renewed interest in its use. Some clinical trials have characterized the effects of TXA on reducing postoperative infection rates and regulating immune responses in patients undergoing surgery. Also, several animal studies suggest potential therapeutic effects of TXA on skeletal diseases such as osteoporosis and fracture healing. Although a direct effect of TXA on the differentiation and function of bone cells in vitro was shown, few mechanisms of action have been reported. Here, we summarize recent findings of the effects of TXA on skeletal diseases and discuss the underlying plasminogen-dependent and -independent mechanisms related to bone metabolism and the immune response. We furthermore discuss potential novel indications for TXA application as a treatment strategy for skeletal diseases.

AB - The worldwide burden of skeletal diseases such as osteoporosis, degenerative joint disease and impaired fracture healing is steadily increasing. Tranexamic acid (TXA), a plasminogen inhibitor and anti-fibrinolytic agent, is used to reduce bleeding with high effectiveness and safety in major surgical procedures. With its widespread clinical application, the effects of TXA beyond anti-fibrinolysis have been noticed and prompted renewed interest in its use. Some clinical trials have characterized the effects of TXA on reducing postoperative infection rates and regulating immune responses in patients undergoing surgery. Also, several animal studies suggest potential therapeutic effects of TXA on skeletal diseases such as osteoporosis and fracture healing. Although a direct effect of TXA on the differentiation and function of bone cells in vitro was shown, few mechanisms of action have been reported. Here, we summarize recent findings of the effects of TXA on skeletal diseases and discuss the underlying plasminogen-dependent and -independent mechanisms related to bone metabolism and the immune response. We furthermore discuss potential novel indications for TXA application as a treatment strategy for skeletal diseases.

U2 - 10.1016/j.apsb.2024.03.033

DO - 10.1016/j.apsb.2024.03.033

M3 - SCORING: Review article

C2 - 39027253

VL - 14

SP - 2869

EP - 2884

JO - ACTA PHARM SIN B

JF - ACTA PHARM SIN B

SN - 2211-3835

IS - 7

ER -